TXG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

139.41M

-8.95%

143.60M

-5.31%

155.21M

-5.94%

Estimates Revision

The market is revising No Change the revenue expectations for 10x Genomics, Inc. (TXG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 22.16%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+22.16%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

0 Sell

Moderate Buy

Current: 15.710

Low

9.00

Averages

13.00

High

18.00

Current: 15.710

Low

9.00

Averages

13.00

High

18.00

BofA

Michael Ryskin

Neutral

maintain

$15 -> $18

2025-12-15

New

Reason

BofA

Michael Ryskin

Price Target

$15 -> $18

2025-12-15

New

maintain

Neutral

Reason

BofA analyst Michael Ryskin raised the firm's price target on 10x Genomics to $18 from $15 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Barclays

NULL

Overweight

maintain

$17 -> $22

2025-12-15

New

Reason

Barclays

Price Target

$17 -> $22

2025-12-15

New

maintain

NULL

Overweight

Reason

Barclays raised the firm's price target on 10x Genomics to $22 from $17 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Citi

Buy -> Neutral

downgrade

$18

2025-12-11

Reason

Citi

Price Target

$18

2025-12-11

downgrade

Buy -> Neutral

Reason

Citi downgraded 10x Genomics to Neutral from Buy with an unchanged price target of $18. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi cites cautious customer spending in 10x's academic and government end markets, an uncertain biotech recovery timing, ramping competition, and a balanced risk/reward post the recent rally for the downgrade.

Piper Sandler

Neutral

maintain

$15 -> $19

2025-11-11

Reason

Piper Sandler

Price Target

$15 -> $19

2025-11-11

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on 10x Genomics to $19 from $15 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.

Canaccord

Buy

maintain

$16 -> $19

2025-11-07

Reason

Canaccord

Price Target

$16 -> $19

2025-11-07

maintain

Buy

Reason

Canaccord raised the firm's price target on 10x Genomics to $19 from $16 and keeps a Buy rating on the shares. The firm said TXG remains one their top picks in Tools after a solid 3Q25, as they are optimistic that the company can reaccelerate growth in the relative near term.

JPMorgan

Neutral

maintain

$13 -> $15

2025-11-07

Reason

JPMorgan

Price Target

$13 -> $15

2025-11-07

maintain

Neutral

Reason

JPMorgan raised the firm's price target on 10x Genomics to $15 from $13 and keeps a Neutral rating on the shares following the Q3 report.

Valuation Metrics

The current forward P/E ratio for 10X Genomics Inc (TXG.O) is -8.62, compared to its 5-year average forward P/E of -104.27. For a more detailed relative valuation and DCF analysis to assess 10X Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-104.27

Current PE

-8.62

Overvalued PE

41.03

Undervalued PE

-249.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-561.62

Current EV/EBITDA

-7.40

Overvalued EV/EBITDA

1272.19

Undervalued EV/EBITDA

-2395.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.49

Current PS

2.13

Overvalued PS

25.44

Undervalued PS

1.53

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TXG News & Events

Events Timeline

No data

News

5.0

12-13Yahoo Finance

Shifts in the Narrative Surrounding 10x Genomics Due to Recent Institutional Purchases and Product Developments

9.5

12-11NASDAQ.COM

Transcript of 10x Genomics (TXG) Earnings for Q4 2024

9.5

12-11NASDAQ.COM

Transcript of 10x Genomics (TXG) Earnings for Q2 2025

People Also Watch

Frequently Asked Questions

What is 10X Genomics Inc (TXG) stock price today?

The current price of TXG is 15.71 USD — it has decreased -0.32 % in the last trading day.

What is 10X Genomics Inc (TXG)'s business?

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

What is the price predicton of TXG Stock?

What is 10X Genomics Inc (TXG)'s revenue for the last quarter?

10X Genomics Inc revenue for the last quarter amounts to 154.88M USD, increased 9.84 % YoY.

What is 10X Genomics Inc (TXG)'s earnings per share (EPS) for the last quarter?

10X Genomics Inc. EPS for the last quarter amounts to -0.28 USD, decreased -44.00 % YoY.

What changes have occurred in the market's expectations for 10X Genomics Inc (TXG)'s fundamentals?

How many employees does 10X Genomics Inc (TXG). have?

10X Genomics Inc (TXG) has 1306 emplpoyees as of December 17 2025.

What is 10X Genomics Inc (TXG) market cap?

Today TXG has the market capitalization of 2.38B USD.